Limits...
Feasibility of imaging esophageal cancer with labeled somatostatin analogue.

Herlin G, Ideström L, Lundell L, Aspelin P, Axelsson R - Int J Mol Imaging (2011)

Bottom Line: Conclusion.Scintigraphic examination with (99m)Tc-depreotide is feasible for imaging esophageal cancer, but the method is not suitable neither for screening or primary diagnosis, because of methods modest sensitivity.Our first results showed high specificity which should be used with caution, as the number of patients was relatively low.

View Article: PubMed Central - PubMed

Affiliation: Division of Medical Imaging and Technology, Department of Clinical Science, Intervention and Technology, Karolinska Institute, 141 86 Stockholm, Sweden.

ABSTRACT
Background. While the surface of a cell normally has some amount of somatostatin receptors, these receptors are overexpressed to a very high degree in multiple neoplastic diseases. No data exist for esophageal carcinoma. Purpose. To find out whether esophageal carcinoma could be imaged using somatostatin receptor scintigraphy. Material and Methods. 34 patients with esophageal lesions were prospectively examined by (99m)Tc-depreotide scintigraphy 2 and 4 hours after injection. Quantitative evaluation of (99m)Tc-depreotide uptake was performed around the lesion (T) and in healthy lung parenchyma (B). The relative uptake was calculated as T-B/B. Scintigraphy results were compared with histopathology from surgery or biopsy specimens from endoscopic ultrasonography. Results. 21 patients had esophageal cancer, and 13 lesions were benign. Visual assessment revealed positive (99m)Tc-depreotide uptake in 16 of the 21 cancers. The 13 patients without cancer had no depreotide uptake. The Mann-Whitney U test showed a statistically significant difference (P < .005) between (99m)Tc-depreotide uptake in malignant and benign lesions, for both the 2-hour and the 4-hour measurements. Conclusion. Scintigraphic examination with (99m)Tc-depreotide is feasible for imaging esophageal cancer, but the method is not suitable neither for screening or primary diagnosis, because of methods modest sensitivity. Our first results showed high specificity which should be used with caution, as the number of patients was relatively low. Further studies are needed to determine the role of the method.

No MeSH data available.


Related in: MedlinePlus

99mTc-depreotide uptake measured 2 hours after injection in patients with esophageal cancer and Barrett's esophagus.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3116512&req=5

fig2: 99mTc-depreotide uptake measured 2 hours after injection in patients with esophageal cancer and Barrett's esophagus.

Mentions: There was no 99mTc-depreotide uptake in the columnar metaplastic mucosa in any of the 13 Barrett's patients, irrespective of the presence of low and high-grade dysplasia in the metaplastic epithelium (Figure 2). The specificity of 99mTc-depreotide scintigraphy in this cohort of patients was thus 1.00, 95% confidence interval 0.77 to 1.00.


Feasibility of imaging esophageal cancer with labeled somatostatin analogue.

Herlin G, Ideström L, Lundell L, Aspelin P, Axelsson R - Int J Mol Imaging (2011)

99mTc-depreotide uptake measured 2 hours after injection in patients with esophageal cancer and Barrett's esophagus.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3116512&req=5

fig2: 99mTc-depreotide uptake measured 2 hours after injection in patients with esophageal cancer and Barrett's esophagus.
Mentions: There was no 99mTc-depreotide uptake in the columnar metaplastic mucosa in any of the 13 Barrett's patients, irrespective of the presence of low and high-grade dysplasia in the metaplastic epithelium (Figure 2). The specificity of 99mTc-depreotide scintigraphy in this cohort of patients was thus 1.00, 95% confidence interval 0.77 to 1.00.

Bottom Line: Conclusion.Scintigraphic examination with (99m)Tc-depreotide is feasible for imaging esophageal cancer, but the method is not suitable neither for screening or primary diagnosis, because of methods modest sensitivity.Our first results showed high specificity which should be used with caution, as the number of patients was relatively low.

View Article: PubMed Central - PubMed

Affiliation: Division of Medical Imaging and Technology, Department of Clinical Science, Intervention and Technology, Karolinska Institute, 141 86 Stockholm, Sweden.

ABSTRACT
Background. While the surface of a cell normally has some amount of somatostatin receptors, these receptors are overexpressed to a very high degree in multiple neoplastic diseases. No data exist for esophageal carcinoma. Purpose. To find out whether esophageal carcinoma could be imaged using somatostatin receptor scintigraphy. Material and Methods. 34 patients with esophageal lesions were prospectively examined by (99m)Tc-depreotide scintigraphy 2 and 4 hours after injection. Quantitative evaluation of (99m)Tc-depreotide uptake was performed around the lesion (T) and in healthy lung parenchyma (B). The relative uptake was calculated as T-B/B. Scintigraphy results were compared with histopathology from surgery or biopsy specimens from endoscopic ultrasonography. Results. 21 patients had esophageal cancer, and 13 lesions were benign. Visual assessment revealed positive (99m)Tc-depreotide uptake in 16 of the 21 cancers. The 13 patients without cancer had no depreotide uptake. The Mann-Whitney U test showed a statistically significant difference (P < .005) between (99m)Tc-depreotide uptake in malignant and benign lesions, for both the 2-hour and the 4-hour measurements. Conclusion. Scintigraphic examination with (99m)Tc-depreotide is feasible for imaging esophageal cancer, but the method is not suitable neither for screening or primary diagnosis, because of methods modest sensitivity. Our first results showed high specificity which should be used with caution, as the number of patients was relatively low. Further studies are needed to determine the role of the method.

No MeSH data available.


Related in: MedlinePlus